Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

20141,603 citationsJournal Articlebronze Open Access

Authors

John C. Byrd · The Ohio State University

Jennifer R. Brown · Dana-Farber Cancer Institute

Susan O’Brien · The University of Texas MD Anderson Cancer Center

Jacqueline C. Barrientos · Hofstra University

Neil E. Kay · Mayo Clinic in Arizona

Nishitha Reddy · Vanderbilt University

Steven Coutré

Abstract

Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 3, pp. 213-223

DOI: 10.1056/nejmoa1400376

Field-Weighted Citation Impact: 100.76